Head and Neck Cancer in the Elderly Population

Seminars in Radiation Oncology

Volumn 22, Issue 4, 2012, Pages 321-333

  Siddiqui, Farzan ^a   Gwede, Clement K ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; CYCLIN D1; PACLITAXEL; PANITUMUMAB; VASCULOTROPIN;

ADVANCED CANCER; AGED; ANEMIA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY FUNCTION; LEUKOPENIA; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MARRIAGE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; TONGUE CANCER; XEROSTOMIA;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COMORBIDITY; DECISION MAKING; GERIATRIC ASSESSMENT; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 84866327795     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.05.009     Document Type: Review

References (101)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
4. Vincent G.K., Velkoff V.A. The next four decades, the older population in the United States: 2010- to 2050. Current Population Reports 2010, 25-1138. US Census Bureau, Washington, DC.
5. Smith B.D., Smith G.L., Hurria A., et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009, 27:2758-2765.
6. Parker S.L., Tong T., Bolden S., et al. Cancer statistics, 1997. CA Cancer J Clin 1997, 47:5-27.
7. Syrigos K.N., Karachalios D., Karapanagiotou E.M., et al. Head and neck cancer in the elderly: An overview on the treatment modalities. Cancer Treat Rev 2009, 35:237-245.
8. Kruse A.L., Bredell M., Luebbers H.T., et al. Head and neck cancer in the elderly: A retrospective study over 10 years (1999-2008). Head Neck Oncol 2010, 2:25.
9. Huang S.H., O'Sullivan B., Waldron J., et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: A single-center cohort study. Int J Radiat Oncol Biol Phys 2011, 79:46-51.
10. León X., Quer M., Agudelo D., et al. Influence of age on laryngeal carcinoma. Ann Otol Rhinol Laryngol 1998, 107:164-169.
11. Koch W.M., Patel H., Brennan J., et al. Squamous cell carcinoma of the head and neck in the elderly. Arch Otolaryngol Head Neck Surg 1995, 121:262-265.
12. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991, 324:1685-1690. The Department of Veterans Affairs Laryngeal Cancer Study Group.
13. Terrell J.E., Fisher S.G., Wolf G.T. Long-term quality of life after treatment of laryngeal cancer. The Veterans Affairs Laryngeal Cancer Study Group. Arch Otolaryngol Head Neck Surg 1998, 124:964-971.
14. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
15. Siddiqui F., Pajak T.F., Watkins-Bruner D., et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 2008, 70:353-360.
16. Fu K.K., Pajak T.F., Trotti A., et al. A radiation therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16.
17. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91:2081-2086.
18. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98.
19. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350:1945-1952.
20. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-1944.
21. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
22. Curran D., Giralt J., Harari P.M., et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007, 25:2191-2197.
23. Mineta H., Borg A., Dictor M., et al. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998, 78:1084-1090.
24. Ang K.K., Smith B.D., Haffty B.G. Prognostic factors in patients with head and neck cancer. Head and Neck Cancer: A Multidisciplinary Approach 2009, 51-75. 3rd ed. L.B. Harrison (Ed.).
25. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
26. Gillison M. HPV and its effect on head and neck cancer prognosis. Clin Adv Hematol Oncol 2010, 8:680-682.
27. Konski A.A., Pajak T.F., Movsas B., et al. Disadvantage of men living alone participating in radiation therapy oncology group head and neck trials. J Clin Oncol 2006, 24:4177-4183.
28. Meyer F., Fortin A., Gélinas M., et al. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. J Clin Oncol 2009, 27:2970-2976.
29. Quinten C., Coens C., Mauer M., et al. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009, 10:865-871.
30. Kowalski L.P., Franco E.L., de Andrade Sobrinho J., et al. Prognostic factors in laryngeal cancer patients submitted to surgical treatment. J Surg Oncol 1991, 48:87-95.
31. Deleyiannis F.W., Thomas D.B., Vaughan T.L., et al. Alcoholism: Independent predictor of survival in patients with head and neck cancer. J Natl Cancer Inst 1996, 88:542-549.
32. Lusinchi A., Bourhis J., Wibault P., et al. Radiation therapy for head and neck cancers in the elderly. Int J Radiat Oncol Biol Phys 1990, 18:819-823.
33. Airoldi M., Cortesina G., Giordano C., et al. Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:161-166.
34. Argiris A., Li Y., Murphy B.A., et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004, 22:262-268.
35. Bhattacharyya N. A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly. Laryngoscope 2003, 113:368-372.
36. Paleri V., Wight R.G., Silver C.E., et al. Comorbidity in head and neck cancer: A critical appraisal and recommendations for practice. Oral Oncol 2010, 46:712-719.
37. Murphy B.A., Ridner S., Wells N., et al. Quality of life research in head and neck cancer: A review of the current state of the science. Crit Rev Oncol Hematol 2007, 62:251-267.
38. Bond S.M., Dietrich M.S., Murphy B.A. Association of age and symptom burden in patients with head and neck cancer. ORL Head Neck Nurs 2011, 29:8-14.
39. El-Deiry M.W., Futran N.D., McDowell J.A., et al. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch Otolaryngol Head Neck Surg 2009, 135:380-384.
40. Terrell J.E., Ronis D.L., Fowler K.E., et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:401-408.
41. Fang F.M., Liu Y.T., Tang Y., et al. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 2004, 100:425-432.
42. Gourin C.G., Boyce B.J., Vaught C.C., et al. Effect of comorbidity on post-treatment quality of life scores in patients with head and neck squamous cell carcinoma. Laryngoscope 2009, 119:907-914.
43. Gourin C.G., McAfee W.J., Neyman K.M., et al. Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck. Laryngoscope 2005, 115:1371-1375.
44. Peters T.T., van der Laan B.F., Plaat B.E., et al. The impact of comorbidity on treatment-related side effects in older patients with laryngeal cancer. Oral Oncol 2011, 47:56-61.
45. Piccirillo J.F., Tierney R.M., Costas I., et al. Prognostic importance of comorbidity in a Hospital-Based Cancer registry. JAMA 2004, 291:2441-2447.
46. Sanabria A., Carvalho A.L., Vartanian J.G., et al. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 2007, 14:1449-1457.
47. Sanabria A., Carvalho A.L., Vartanian J.G., et al. Factors that influence treatment decision in older patients with resectable head and neck cancer. Laryngoscope 2007, 117:835-840.
48. Wan Leung S., Lee T.F., Chien C.Y., et al. Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires. BMC Cancer 2011, 11:128.
49. Derks W., De Leeuw R., Winnubst J., et al. Elderly patients with head and neck cancer: Physical, social and psychological aspects after 1 year. Acta Otolaryngol 2004, 124:509-514.
50. Derks W., de Leeuw R.J., Hordijk G.J. Elderly patients with head and neck cancer: The influence of comorbidity on choice of therapy, complication rate, and survival. Curr Opin Otolaryngol Head Neck Surg 2005, 13:92-96.
51. Singh B., Cordeiro P.G., Santamaria E., et al. Factors associated with complications in microvascular reconstruction of head and neck defects. Plast Reconstr Surg 1999, 103:403-411.
52. Borggreven P.A., Kuik D.J., Quak J.J., et al. Comorbid condition as a prognostic factor for complications in major surgery of the oral cavity and oropharynx with microvascular soft tissue reconstruction. Head Neck 2003, 25:808-815.
53. Sanabria A., Carvalho A.L., Melo R.L., et al. Predictive factors for complications in elderly patients who underwent head and neck oncologic surgery. Head Neck 2008, 30:170-177.
54. Piccirillo J.F., Wells C.K., Sasaki C.T., et al. New clinical severity staging system for cancer of the larynx. Five-year survival rates. Ann Otol Rhinol Laryngol 1994, 103:83-92.
55. Datema F.R., Ferrier M.B., van der Schroeff M.P., et al. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 2010, 32:728-736.
56. Piccirillo J.F. Importance of comorbidity in head and neck cancer. Laryngoscope 2000, 110:593-602.
57. Derks W., de Leeuw J.R., Hordijk G.J., et al. Reasons for non-standard treatment in elderly patients with advanced head and neck cancer. Eur Arch Otorhinolaryngol 2005, 262:21-26.
58. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55:241-252.
59. Kumar A., Soares H.P., Balducci L., et al. Treatment tolerance and efficacy in geriatric oncology: A systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 2007, 25:1272-1276.
60. Borggreven P.A., Verdonck-de Leeuw I.M., Muller M.J., et al. Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: Pretreatment values of a prospective study. Eur Arch Otorhinolaryngol 2007, 264:651-657.
61. Oozeer N.B., Benbow J., Downs C., et al. The effect of comorbidity on quality of life during radiotherapy in head and neck cancer. Otolaryngol Head Neck Surg 2008, 139:268-272.
62. Fang F.M., Chien C.Y., Tsai W.L., et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-A longitudinal study. Int J Radiat Oncol Biol Phys 2008, 72:356-364.
63. Fang F.M., Chiu H.C., Kuo W.R., et al. Health-related quality of life for nasopharyngeal carcinoma patients with cancer-free survival after treatment. Int J Radiat Oncol Biol Phys 2002, 53:959-968.
64. Fang F.M., Tsai W.L., Lee T.F., et al. Multivariate analysis of quality of life outcome for nasopharyngeal carcinoma patients after treatment. Radiother Oncol 2010, 97:263-269.
65. Huguenin P., Sauer M., Glanzmann C., et al. Radiotherapy for carcinomas of the head and neck in elderly patients. Strahlenther Onkol 1996, 172:485-488.
66. Zachariah B., Balducci L., Venkattaramanabalaji G.V., et al. Radiotherapy for cancer patients aged 80 and older: A study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 1997, 39:1125-1129.
67. Mitsuhashi N., Hayakawa K., Yamakawa M., et al. Cancer in patients aged 90 years or older: Radiation therapy. Radiology 1999, 211:829-833.
68. Allal A.S., Maire D., Becker M., et al. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. Cancer 2000, 88:648-652.
69. Schofield C.P., Sykes A.J., Slevin N.J., et al. Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol 2003, 69:37-42.
70. Koussis H., Scola A., Bergamo F., et al. Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: A phase II study in elderly patients or patients with poor performance status. Anticancer Res 2008, 28:1383-1388.
71. Boscolo-Rizzo P., Muzzi E., Trabalzini F., et al. Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2011, 268:1349-1355.
72. Tsukuda M., Ishitoya J., Mikami Y., et al. Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 2009, 64:945-952.
73. Jensen A.D., Bergmann Z.P., Garcia-Huttenlocher H., et al. Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: A single-centre experience. Head Neck Oncol 2010, 2:34.
74. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: An EORTC randomized trial. Eur J Cancer 1990, 26:779-780.
75. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006, 368:843-854.
76. Baujat B., Bourhis J., Blanchard P., et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010, CD002026.
77. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
78. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004, 22:69-76.
79. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27:843-850.
80. Pignon J.P., le Maître A., Maillard E., et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
81. Cohen J.L. Pharmacokinetic changes in aging. Am J Med 1986, 80:31-38.
82. Hurria A., Lichtman S.M. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 2007, 14:32-43.
83. Daugaard G., Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 1989, 25:1-9.
84. Lichtman S.M. Physiological aspects of aging. Implications for the treatment of cancer. Drugs Aging 1995, 7:212-225.
85. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
86. Christensen M.E. The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 1998, 45:121-134.
87. Grandis J.R., Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53:3579-3584.
88. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-Year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
89. O'Malley B.W., Weinstein G.S., Snyder W., et al. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006, 116:1465-1472.
90. Bhayani M.K., Holsinger F.C., Lai S.Y. A shifting paradigm for patients with head and neck cancer: Transoral robotic surgery (TORS). Oncology (Williston Park) 2010, 24:1010-1015.
91. Hurtuk A., Agrawal A., Old M., et al. Outcomes of transoral robotic surgery: A preliminary clinical experience. Otolaryngol Head Neck Surg 2011, 145:248-253.
92. Hurtuk A.M., Marcinow A., Agrawal A., et al. Quality-of-life outcomes in transoral robotic surgery. Otolaryngol Head Neck Surg 2012, 146:68-73.
93. Yamauchi K., Fujioka Y., Kohno N. Sentinel node navigation surgery versus observation as a management strategy for early tongue carcinoma. Head Neck 2012, 34:568-572.
94. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136.
95. Siddiqui F., Raben D., Lu J.J., et al. Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther 2011, 11:1429-1436.
96. Siddiqui F., Patel M., Khan M., et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009, 74:1047-1053.
97. Mendenhall N.P., Malyapa R.S., Su Z., et al. Proton therapy for head and neck cancer: Rationale, potential indications, practical considerations, and current clinical evidence. Acta Oncol 2011, 50:763-771.
98. Vermorken J.B., Stohlmacher J., Davidenko I., et al. Primary efficacy and safety results of spectrum, a phase 3 trial in patients (pts) with recurrent and/or metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (PMAB). Ann Oncol 2010, 21:12.
99. Vermorken J., Stöhlmacher J., Oliner K., et al. Safety and efficacy of panitumumab (pmab) in HPV positive (+) and HPV negative (-) recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of the phase 3 spectrum trial. The 2011 European Multidisciplinary Cancer Congress 2011.
100. Bianchini C., Ciorba A., Pelucchi S., et al. Targeted therapy in head and neck cancer. Tumori 2011, 97:137-141.
101. Burgos-Tiburcio A., Santos E.S., Arango B.A., et al. Development of targeted therapy for squamous cell carcinomas of the head and neck. Expert Rev Anticancer Ther 2011, 11:373-386.